Safety

	S1A: Need for Carcinogenicity Studies of Pharmaceuticals Date: 2002-12-23
	S1B: Testing for Carcinogenicity of Pharmaceuticals Date: 2000-03-24
	S1C: Dose Selection for Carcinogenicity Studies of Pharmaceuticals Date: 2002-12-23
	S1C(R): Addendum to "Dose Selection for Carcinogenicity Studies of Pharmaceuticals" Addition of a Limit Dose and Related Notes Date: 2000-03-24
	S2A: Guidance on Specific Aspects Of Regulatory Genotoxicity Tests For Pharmaceuticals Date: 2002-12-23
	S2B: Genotoxicity: A Standard Battery for Genotoxcity Testing of Pharmaceuticals Date: 2000-03-24
	S3A: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies Date: 2002-12-23
	S3B: Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies Date: 2002-12-23
	S4A: Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing) Date: 2000-03-24
	S5A: Detection of Toxicity to Reproduction for Medicinal Products Date: 2002-12-23
	S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Date: 2003-02-10
	S7A: Safety Pharmacology Studies for Human Pharmaceuticals Date: 2006-03-31
	S7B: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals Date: 2006-04-05
	Health Canada Question and Answer Document Regarding the ICH S7B and E14 Guidances Date: 2006-11-30
	QT/QTc Interval Prolongation